Elite Pharmaceuticals, Inc. (ELTP)

Elite Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	7.11	7.11	7.83	8.54	3.19	1.13
Cash & Cash Equivalents	7.11	7.11	7.83	8.54	3.19	1.13
Cash Growth	-9.27%	-9.27%	-8.24%	167.33%	182.11%	-50.31%
Receivables	19.45	19.45	3.09	3.06	3.5	4.11
Inventory	12.93	12.93	9.55	6.74	5.01	4.14
Other Current Assets	0.52	0.52	1.03	0.53	0.49	0.87
Total Current Assets	40.01	40.01	21.51	18.86	12.19	10.25
Property, Plant & Equipment	14.61	14.61	10.44	6.98	6.86	7.59
Long-Term Investments	0.43	0.43	0.02	0.41	0.41	0.4
Intangible Assets	25.36	6.34	6.34	6.63	6.63	6.63
Other Long-Term Assets	22.26	22.26	2.58	2.26	0.09	0.08
Total Long-Term Assets	43.64	43.64	19.39	16.29	13.99	14.71
Total Assets	83.65	83.65	40.9	35.15	26.19	24.96
Accounts Payable	2.71	2.71	2.45	1.43	0.93	1.58
Deferred Revenue	0.01	0.01	0.01	0.01	0.01	0.18
Current Debt	5.02	5.02	0.33	0.56	0.6	2.06
Other Current Liabilities	5.3	5.3	5.05	4.69	4.27	4.82
Total Current Liabilities	13.05	13.05	7.83	6.69	5.81	8.64
Long-Term Debt	3.28	3.28	3.56	2.22	1.78	1.97
Other Long-Term Liabilities	9.74	9.74	0.54	1.01	2.45	3.69
Total Long-Term Liabilities	13.02	13.02	4.1	3.23	4.23	5.66
Total Liabilities	26.07	26.07	11.94	9.93	10.04	14.3
Total Debt	11.74	11.74	3.89	2.78	2.38	4.03
Debt Growth	201.95%	201.95%	39.75%	16.95%	-40.95%	1.20%
Common Stock	1.07	1.07	1.01	1.01	1.01	0.84
Retained Earnings	-116.39	-116.39	-136.5	-140.06	-148.96	-154.05
Comprehensive Income	0	0	0	0	0	0
Shareholders' Equity	57.58	57.58	28.96	25.22	16.15	10.66
Total Liabilities and Equity	83.65	83.65	40.9	35.15	26.19	24.96
Net Cash / Debt	-4.63	-4.63	3.94	5.75	0.81	-2.9
Net Cash / Debt Growth	-	-	-31.44%	606.63%	-	-
Net Cash Per Share	-0.00	-0.00	0.00	0.01	0.00	-0.00
Working Capital	26.96	26.96	13.68	12.17	6.38	1.61
Book Value Per Share	0.06	0.06	0.03	0.02	0.02	0.01

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.